Alvotech General Counsel Resigns, New CEO Takes Over
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 30 2026
0mins
Should l Buy ALVO?
Source: Newsfilter
- Executive Change: Alvotech's General Counsel Tanya Zharov has announced her resignation after six years, during which she played a crucial role in preparing the company for public listings across multiple markets, highlighting potential challenges in executive stability.
- Leadership Transition: New CEO Lisa Graver will take over Zharov's role, marking a significant shift in the company's leadership that could impact strategic direction and market confidence.
- Continued Support: Although Zharov is stepping down, she will continue to support the company for several months to ensure a smooth transition, indicating the company's commitment to stability and continuity during executive changes.
- Global Market Expansion: Alvotech has launched five biosimilars in various markets and is developing nine additional candidates, demonstrating its potential for growth and competitive positioning in the global biopharmaceutical sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ALVO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ALVO
Wall Street analysts forecast ALVO stock price to rise
4 Analyst Rating
3 Buy
0 Hold
1 Sell
Moderate Buy
Current: 3.200
Low
5.00
Averages
8.75
High
10.00
Current: 3.200
Low
5.00
Averages
8.75
High
10.00
About ALVO
Alvotech SA is a biotechnology company. The Company is focused on the development and manufacture of biosimilar medicines for patients globally. It is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). It has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Alvotech Q1 Revenue Declines 20.3% Missing Estimates
- Revenue Decline: Alvotech reported Q1 revenue of $105.9 million, reflecting a 20.3% year-over-year decline, which missed market expectations by $34.95 million, indicating significant competitive pressures.
- Adjusted EBITDA: The company achieved an adjusted EBITDA of $24.4 million, which, while positive, suggests challenges in profitability as it shows a decline compared to the previous year, potentially impacting investor confidence.
- Stable Gross Margin: Despite the revenue drop, Alvotech maintained a gross margin of 57%, indicating effective cost control; however, the ongoing revenue decline may threaten future profitability.
- Uncertain Market Outlook: With revenue falling short of expectations, Alvotech faces increased market pressure, prompting investors to closely monitor the company's strategic adjustments and market responses to assess its long-term growth potential.
See More
Alvotech General Counsel Resigns, New CEO Takes Over
- Executive Change: Alvotech's General Counsel Tanya Zharov has announced her resignation after six years, during which she played a crucial role in preparing the company for public listings across multiple markets, highlighting potential challenges in executive stability.
- Leadership Transition: New CEO Lisa Graver will take over Zharov's role, marking a significant shift in the company's leadership that could impact strategic direction and market confidence.
- Continued Support: Although Zharov is stepping down, she will continue to support the company for several months to ensure a smooth transition, indicating the company's commitment to stability and continuity during executive changes.
- Global Market Expansion: Alvotech has launched five biosimilars in various markets and is developing nine additional candidates, demonstrating its potential for growth and competitive positioning in the global biopharmaceutical sector.
See More
Alvotech Files Annual Report for 2025 with SEC
- Annual Report Submission: Alvotech filed its 2025 Annual Report with the SEC on March 30, 2026, providing detailed financial information aimed at enhancing transparency and boosting investor confidence.
- Biosimilar Market Focus: The company specializes in the development and manufacturing of biosimilars, with five products already approved and marketed globally, demonstrating its strong competitive position in the biopharmaceutical sector.
- Development Pipeline: Alvotech has nine disclosed biosimilar candidates in development targeting autoimmune disorders, eye diseases, osteoporosis, respiratory diseases, and cancer, showcasing its extensive market potential.
- Global Strategic Partnerships: The company has formed a network of strategic commercial partnerships across the U.S., Europe, Japan, China, and other Asian countries, aiming to leverage local expertise to expand its market reach and enhance global operational capabilities.
See More
Alvotech Releases Annual Report for 2025
- Annual Report Release: Alvotech published its 2025 Annual Report on March 30, 2026, which is available in the investor relations section of the company’s website, marking an enhancement in transparency and information disclosure.
- Biosimilar Market Positioning: The company has already approved and marketed five biosimilars in multiple global markets, including Humira® and Stelara®, demonstrating its competitiveness and market recognition in the biopharmaceutical sector.
- Pipeline Expansion: Alvotech currently has nine biosimilar candidates under development targeting autoimmune disorders, eye diseases, osteoporosis, respiratory diseases, and cancer, indicating its commitment to addressing diverse patient needs.
- Global Strategic Partnerships: The establishment of a strategic commercial partnership network across the U.S., Europe, Japan, China, and other Asian countries enhances Alvotech's influence in global markets and leverages local expertise.
See More
Alvotech Files Annual Report for 2025
- Annual Report Submission: Alvotech filed its 2025 Annual Report with the SEC on March 30, 2026, providing detailed financial information to enhance transparency and comply with regulatory requirements.
- Biosimilar Market Presence: The company has five biosimilars approved and marketed globally, including Humira® and Stelara®, indicating strong competitiveness and market recognition in the biopharmaceutical sector.
- Pipeline Expansion: Alvotech is developing nine biosimilar candidates targeting autoimmune diseases, eye disorders, and more, demonstrating its ongoing commitment to innovation and strategic positioning in drug development.
- Global Partnership Network: The company has formed strategic partnerships across markets including the U.S., Europe, Japan, and China, aiming to leverage local expertise to enhance global market penetration and competitive advantage.
See More
Alvotech Q4 2025 Earnings Call Highlights
- Financial Performance Boost: In Q4 2025, total revenues reached $173 million, a 13% year-over-year increase, with licensing revenues comprising 75%, driving gross margin up to 66% and adjusted EBITDA to $69 million, showcasing success in capital market transactions.
- Pipeline Expansion: Alvotech currently has 30 biosimilars in development and plans to establish a second manufacturing site with a U.S.-based CMO partner to enhance supply chain flexibility and resilience, ensuring future product availability in the market.
- Market Expansion Strategy: The collaboration with Teva to launch Selarsdi marks the company's second biosimilar launch in the U.S., while approvals for golimumab, denosumab, and aflibercept across Europe, the UK, and Japan further broaden market reach.
- Optimistic Outlook: Management reaffirmed the 2026 revenue guidance of $650 million to $700 million, expecting continued double-digit sales growth, with adjusted EBITDA projected to rise to $180 million to $220 million, reflecting confidence in future market opportunities.
See More
Alvotech Q1 Revenue Declines 20.3% Missing Estimates
- Revenue Decline: Alvotech reported Q1 revenue of $105.9 million, reflecting a 20.3% year-over-year decline, which missed market expectations by $34.95 million, indicating significant competitive pressures.
- Adjusted EBITDA: The company achieved an adjusted EBITDA of $24.4 million, which, while positive, suggests challenges in profitability as it shows a decline compared to the previous year, potentially impacting investor confidence.
- Stable Gross Margin: Despite the revenue drop, Alvotech maintained a gross margin of 57%, indicating effective cost control; however, the ongoing revenue decline may threaten future profitability.
- Uncertain Market Outlook: With revenue falling short of expectations, Alvotech faces increased market pressure, prompting investors to closely monitor the company's strategic adjustments and market responses to assess its long-term growth potential.
See More
Alvotech General Counsel Resigns, New CEO Takes Over
- Executive Change: Alvotech's General Counsel Tanya Zharov has announced her resignation after six years, during which she played a crucial role in preparing the company for public listings across multiple markets, highlighting potential challenges in executive stability.
- Leadership Transition: New CEO Lisa Graver will take over Zharov's role, marking a significant shift in the company's leadership that could impact strategic direction and market confidence.
- Continued Support: Although Zharov is stepping down, she will continue to support the company for several months to ensure a smooth transition, indicating the company's commitment to stability and continuity during executive changes.
- Global Market Expansion: Alvotech has launched five biosimilars in various markets and is developing nine additional candidates, demonstrating its potential for growth and competitive positioning in the global biopharmaceutical sector.
See More
Alvotech Files Annual Report for 2025 with SEC
- Annual Report Submission: Alvotech filed its 2025 Annual Report with the SEC on March 30, 2026, providing detailed financial information aimed at enhancing transparency and boosting investor confidence.
- Biosimilar Market Focus: The company specializes in the development and manufacturing of biosimilars, with five products already approved and marketed globally, demonstrating its strong competitive position in the biopharmaceutical sector.
- Development Pipeline: Alvotech has nine disclosed biosimilar candidates in development targeting autoimmune disorders, eye diseases, osteoporosis, respiratory diseases, and cancer, showcasing its extensive market potential.
- Global Strategic Partnerships: The company has formed a network of strategic commercial partnerships across the U.S., Europe, Japan, China, and other Asian countries, aiming to leverage local expertise to expand its market reach and enhance global operational capabilities.
See More
Alvotech Releases Annual Report for 2025
- Annual Report Release: Alvotech published its 2025 Annual Report on March 30, 2026, which is available in the investor relations section of the company’s website, marking an enhancement in transparency and information disclosure.
- Biosimilar Market Positioning: The company has already approved and marketed five biosimilars in multiple global markets, including Humira® and Stelara®, demonstrating its competitiveness and market recognition in the biopharmaceutical sector.
- Pipeline Expansion: Alvotech currently has nine biosimilar candidates under development targeting autoimmune disorders, eye diseases, osteoporosis, respiratory diseases, and cancer, indicating its commitment to addressing diverse patient needs.
- Global Strategic Partnerships: The establishment of a strategic commercial partnership network across the U.S., Europe, Japan, China, and other Asian countries enhances Alvotech's influence in global markets and leverages local expertise.
See More
Alvotech Files Annual Report for 2025
- Annual Report Submission: Alvotech filed its 2025 Annual Report with the SEC on March 30, 2026, providing detailed financial information to enhance transparency and comply with regulatory requirements.
- Biosimilar Market Presence: The company has five biosimilars approved and marketed globally, including Humira® and Stelara®, indicating strong competitiveness and market recognition in the biopharmaceutical sector.
- Pipeline Expansion: Alvotech is developing nine biosimilar candidates targeting autoimmune diseases, eye disorders, and more, demonstrating its ongoing commitment to innovation and strategic positioning in drug development.
- Global Partnership Network: The company has formed strategic partnerships across markets including the U.S., Europe, Japan, and China, aiming to leverage local expertise to enhance global market penetration and competitive advantage.
See More
Alvotech Q4 2025 Earnings Call Highlights
- Financial Performance Boost: In Q4 2025, total revenues reached $173 million, a 13% year-over-year increase, with licensing revenues comprising 75%, driving gross margin up to 66% and adjusted EBITDA to $69 million, showcasing success in capital market transactions.
- Pipeline Expansion: Alvotech currently has 30 biosimilars in development and plans to establish a second manufacturing site with a U.S.-based CMO partner to enhance supply chain flexibility and resilience, ensuring future product availability in the market.
- Market Expansion Strategy: The collaboration with Teva to launch Selarsdi marks the company's second biosimilar launch in the U.S., while approvals for golimumab, denosumab, and aflibercept across Europe, the UK, and Japan further broaden market reach.
- Optimistic Outlook: Management reaffirmed the 2026 revenue guidance of $650 million to $700 million, expecting continued double-digit sales growth, with adjusted EBITDA projected to rise to $180 million to $220 million, reflecting confidence in future market opportunities.
See More
